Allergy Therapeutics (AGY)
21/05/2018 - 12:25 RNS
Hardman & Co Research Hardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registration 21-May-2018 / 12:25 GMT/BST Hardman & Co Research: Opening the door to registration AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (SCI...
21/05/2018 - 10:05 StockMarketWire
Allergy Therapeutics said Monday a study to explore the safety and response of its grass allergy product drug met its prim...
21/05/2018 - 07:00 RNS
RNS Number: 6504O Allergy Therapeutics PLC 21 May 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study - Primary endpoint met with highly statistically significant dose-response relationship established - - Optimal Phase III dose identi...
14/05/2018 - 07:00 RNS
RNS Number: 8725N Allergy Therapeutics PLC 14 May 2018 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " Group " ) Allergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant, Microcrystalline Tyrosine (MCT ), in The Journal of Immunology Novel Findings Further...
|03-08-12||Markets: FTSE 100 climbs higher on Friday||Interactive Investor|
|18-04-12||Markets: FTSE 100 uncertain on Wednesday||Interactive Investor|
|06-12-11||Markets: FTSE 100 flat on Tuesday||Interactive Investor|
|26-04-11||Markets: Manufacturing data lifts FTSE 100||Interactive Investor|
|26-04-11||FDA approval lifts shares in Allergy Therapeutics||Interactive Investor|
|28-03-11||Markets: FTSE 100 trims gains on Monday||Interactive Investor|